Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
- PMID: 11136287
- DOI: 10.1046/j.1365-2036.2001.00896.x
Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
Abstract
Background: Gastrointestinal symptoms are commonly reported as side-effects of oral hypoglycaemic drugs. It may be very difficult to distinguish between spontaneous and truly drug-related symptoms due to the high background incidence of gastrointestinal symptoms. Gastrointestinal symptoms in diabetic patients have also been linked to factors associated with long-standing disease and suboptimal control.
Aim: To explore the association between gastrointestinal symptoms and treatment with oral hypoglycaemic drugs in a large cohort of subjects with type 2 diabetes.
Patients and methods: 956 subjects with type 2 diabetes participated in the study. All subjects completed a validated, self-administered questionnaire on gastrointestinal symptoms, diabetes, drug use and various potential risk factors for gastrointestinal symptoms. The association between oral hypoglycaemics and nine gastrointestinal symptom groups was assessed based on logistic regression.
Results: 405 of the 956 patients used oral hypoglycaemic drugs. Metformin use was independently associated with chronic diarrhoea (odds ratio 3.08, 95% CI: 1.29-7.36, P < 0.02) and with faecal incontinence (odds ratio 1.95, 95% CI: 1.10-3.47, P < 0.05). Use of sulphonylureas was associated with less abdominal pain, but not with any other gastrointestinal symptom.
Conclusions: Troublesome gastrointestinal symptoms do not appear to be caused by oral hypoglycaemics, except for diarrhoea and faecal incontinence, which are strongly and independently associated with metformin use.
Similar articles
-
Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.J Clin Pharm Ther. 2015 Aug;40(4):461-5. doi: 10.1111/jcpt.12290. Epub 2015 May 29. J Clin Pharm Ther. 2015. PMID: 26032654
-
Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes.Postgrad Med. 2010 Mar;122(2):112-20. doi: 10.3810/pgm.2010.03.2128. Postgrad Med. 2010. PMID: 20203462
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study.Diabetes Care. 2019 Jun;42(6):1027-1033. doi: 10.2337/dc18-2182. Epub 2019 Mar 18. Diabetes Care. 2019. PMID: 30885951
-
Oral hypoglycaemics. When not to use what.Aust Fam Physician. 2002 Jul;31(7):637-43. Aust Fam Physician. 2002. PMID: 12143325 Review.
Cited by
-
The Association Between Fasting C-peptide and Gastrointestinal Symptoms of Gastroparesis in Type 2 Diabetic Patients.J Neurogastroenterol Motil. 2017 Apr 30;23(2):254-261. doi: 10.5056/jnm16091. J Neurogastroenterol Motil. 2017. PMID: 27820956 Free PMC article.
-
CCR2 upregulation in DRG neurons plays a crucial role in gastric hyperalgesia associated with diabetic gastropathy.Mol Pain. 2018 Jan-Dec;14:1744806917751322. doi: 10.1177/1744806917751322. Mol Pain. 2018. PMID: 29359616 Free PMC article.
-
Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011.Drug Saf. 2011 Dec 1;34(12):1191-202. doi: 10.2165/11593810-000000000-00000. Drug Saf. 2011. PMID: 22077507
-
Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.Diabetes Technol Ther. 2015 Jan;17(1):35-42. doi: 10.1089/dia.2014.0188. Diabetes Technol Ther. 2015. PMID: 25375397 Free PMC article.
-
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.Drug Des Devel Ther. 2016 Aug 10;10:2525-34. doi: 10.2147/DDDT.S110712. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27570447 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical